PONTACID FORTE TABLET

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

MEFENAMIC ACID

Boleh didapati daripada:

DUOPHARMA (M) SDN. BHD.

INN (Nama Antarabangsa):

MEFENAMIC ACID

Unit dalam pakej:

1000 Tablet Tablets

Dikeluarkan oleh:

DUOPHARMA (M) SDN. BHD.

Risalah maklumat

_Consumer Medication Information Leaflet (RIMUP)_
_ _
1
PONTACID FORTE TABLET
Mefenamic Acid (250mg)
WHAT IS IN THE LEAFLET
1.
What
PONTACID
is
used
for
2.
How PONTACID work
3.
Before you use PONTACID
4.
How to use PONTACID
5.
While you are using it
6.
Side effects
7.
Storage
and
Disposal
of
PONTACID
8.
Product Description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of Revision
WHAT PONTACID IS USED FOR
PONTACID
capsule
PONTACID
is
used
in
the
treatment
of
menstrual
cramps
(period
pain)
and
heavy
menstrual periods.
It is also used to relieve mild to
moderate
pain
such
as
dental
pain
and
soft
tissue
pain,
osteoarthritis (degenerative joint
disease),
rheumatoid
arthritis
(systemic inflammatory disorder
that affects joints).
HOW PONTACID WORKS
PONTACID
capsule_ _
contains
the active ingredient mefenamic
acid.
PONTACID_ _belongs to a group
of
medicines
called
Non-
Steroidal
Anti-Inflammatory
Drugs (or NSAID) which relief
pain, inflammation and fever.
BEFORE YOU USE PONTACID
_-_
_When you must not use it_
Do not take this medicine if you
have an allergy to:

mefenamic
acid,
the
active
ingredient

any of the other ingredients
listed
at
the
end
of
this
leaflet
Do not take PONTACID if:

you had diarrhoea with this
medicine
in
the
past.
Diarrhoea may recur if you
take PONTACID again.

you
have
or
have
had
ulceration
or
inflammation
of the stomach or intestinal.

you
have
impaired
kidney
function.

you have had bronchospasm
(constriction of your airway),
rhinitis (Inflammation of the
nasal
mucous
membrane)
,
urticaria
(itching
or
hives)
and
the
symptoms
become
worsen caused by Aspirin or
NSAIDs.
Do not give PONTACID to a
child under 14 years. The safety
and
effectiveness
of
PONTACID
in
children
have
not been established.
Do not take this medicine after
the expiry date printed on the
pack or if the packaging is torn
or shows signs of tampering.
If it has expired or is damaged,
return it to your pharmacist for
disposal.
If you are not sure whether you
should
start
taking
this
medicine, talk to

Ciri produk

[Page 1/2]
[Revision Date: 26.03.2019]
PONTACID
[DUOPHARMA (M) SDN BHD]
DESCRIPTION:
PONTACID CAPSULE 250 MG : A size 1, light blue / ivory capsule with
marking ‘DUO 861’.
PONTACID FORTE TABLET 500 MG : A blue, oblong, 17mm tablet with
marking ‘dp 500’ on one side.
COMPOSITION:
PONTACID CAPSULE 250 MG: Each capsule contains Mefenamic Acid 250 mg.
PONTACID FORTE TABLET 500 MG: Each tablet contains Mefenamic Acid 500
mg.
PHARMACODYNAMICS:
Mefenamic Acid has analgesic, anti-inflammatory and anti-pyretic
action. It inhibits the enzymes of prostaglandin synthetase and also
antagonizes the actions of prostaglandin
at the receptor sites. These effects may also be responsible for its
effectiveness in the treatment of primary dysmenorrhoea. The pain of
primary dysmenorrhoea is thought
to be due to increased abnormal uterine activity and uterine
ischaemia, probably induced by release of PGF
2
α
or due to increase in the ratio of PGF
2
α
: PGE
2
. Prostaglandins
are also believed to be responsible, at least in some part, for the
symptoms of menorrhagia.
PHARMACOKINETICS:
Single and multiple studies have shown that mefenamic acid usually
reaches peak plasma levels 2 to 4 hours after oral administration with
a half life of 2 hours. Mefenamic
acid and its metabolites are firmly bound to plasma proteins. Two
distinct metabolic products, one a hydroxymethyl derivative and the
other a carboxy derivative, have been
identified in both plasma and urine. Mefenamic acid and its two
metabolic derivatives become conjugated with glucuronic acid through
an ester linkage which is alkali labile
and are excreted principally in the urine, but also to some extent in
the bile and faeces. Following a single dose, 67% of the total dose is
excreted in the urine as unchanged
drug or as one of two metabolites. 20% to 25% of the dose is excreted
in the faeces during the first three days.
INDICATIONS:
For treatment of primary dysmenorrhoea and primary menorrhagia. Short
term relief of mild to moderate pain such as dental pain and soft
tissue